Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 207 articles: HTML format

Single Articles

July 2024
1. DUIN JJ, de Barros HA, van Leeuwen PJ, van der Poel HG, et al
   Reply: Considerations Surrounding the Sentinel Lymph Node in Prostate Cancer and Unanswered Questions.
   J Nucl Med. 2024 Jul 25:jnumed.124.267658. doi: 10.2967/jnumed.124.267658.
   PubMed    
   
   
   
2. AH-THIANE L, Ferrer L, Supiot S, Rousseau C, et al
   Considerations Surrounding the Sentinel Lymph Node in Prostate Cancer and Unanswered Questions.
   J Nucl Med. 2024 Jul 25:jnumed.124.267477. doi: 10.2967/jnumed.124.267477.
   PubMed    
   
   
   
3. BASACO BERNABEU T, Mansi R, Del Pozzo L, Zanger S, et al
   (61)Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging.
   J Nucl Med. 2024 Jul 18:jnumed.123.267126. doi: 10.2967/jnumed.123.267126.
   PubMed     Abstract available
   
   
   
4. BUTEAU JP, Kostos L, Alipour R, Jackson P, et al
   Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [(161)Tb]Tb-PSMA-I&T.
   J Nucl Med. 2024 Jul 11:jnumed.124.267650. doi: 10.2967/jnumed.124.267650.
   PubMed     Abstract available
   
   
   
5. ELLS Z, Grogan TR, Czernin J, Dahlbom M, et al
   Dosimetry of [(177)Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis.
   J Nucl Med. 2024 Jul 3:jnumed.124.267452. doi: 10.2967/jnumed.124.267452.
   PubMed     Abstract available
   
   
   
6. RATHKE H, Winter E, Bruchertseifer F, Rohrich M, et al
   Deescalated (225)Ac-PSMA-617 Versus (177)Lu/(225)Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients.
   J Nucl Med. 2024;65:1057-1063.
   PubMed     Abstract available
   
   
   June 2024
7. BAUCKNEHT M, Lanfranchi F, Albano D, Triggiani L, et al
   Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).
   J Nucl Med. 2024 Jun 27:jnumed.124.267586. doi: 10.2967/jnumed.124.267586.
   PubMed     Abstract available
   
   
   
8. KUO PH, Esposito G, Ulaner GA, Yoo D, et al
   Interreader and Intrareader Reproducibility of (18)F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies.
   J Nucl Med. 2024 Jun 13:jnumed.123.267306. doi: 10.2967/jnumed.123.267306.
   PubMed     Abstract available
   
   
   
9. EVANGELISTA L, Zattoni F, Burei M, Bertin D, et al
   A Prospective Randomized Multicenter Study on the Impact of [(18)F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer.
   J Nucl Med. 2024 Jun 6:jnumed.123.267355. doi: 10.2967/jnumed.123.267355.
   PubMed     Abstract available
   
   
   
10. PHAM TT, Hungnes IN, Rivas C, Cleaver J, et al
    Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of (99m)Tc and (188)Re Theranostic Agents for Prostate Cancer.
    J Nucl Med. 2024 Jun 6:jnumed.124.267450. doi: 10.2967/jnumed.124.267450.
    PubMed     Abstract available
    
    
    
11. SEIFERT R, Telli T, Lapa C, Desaulniers M, et al
    Safety and Efficacy of Extended Therapy with [(177)Lu]Lu-PSMA: A German Multicenter Study.
    J Nucl Med. 2024;65:909-916.
    PubMed     Abstract available
    
    
    May 2024
12. PANDIT-TASKAR N, O'Donoghue JA, Chetty D, Max S, et al
    A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 May 23:jnumed.124.267416. doi: 10.2967/jnumed.124.267416.
    PubMed     Abstract available
    
    
    
13. IMBERTI C, De Gregorio R, Korsen JA, Hoang TT, et al
    CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
    J Nucl Med. 2024 May 23:jnumed.123.267107. doi: 10.2967/jnumed.123.267107.
    PubMed     Abstract available
    
    
    
14. FLEMING MT, Hermsen R, Purysko AS, Chau A, et al
    True-Positive (18)F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study.
    J Nucl Med. 2024 May 23:jnumed.123.267271. doi: 10.2967/jnumed.123.267271.
    PubMed     Abstract available
    
    
    
15. ZANG J, Yang Y, Chen S, Wang C, et al
    Diagnostic Performance of [(18)F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard.
    J Nucl Med. 2024 May 9:jnumed.123.266940. doi: 10.2967/jnumed.123.266940.
    PubMed     Abstract available
    
    
    
16. YADAV S, Jiang F, Kurkowska S, Saelee R, et al
    Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.
    J Nucl Med. 2024 May 9:jnumed.123.267208. doi: 10.2967/jnumed.123.267208.
    PubMed     Abstract available
    
    
    
17. MORADI TUCHAYI A, Yadav S, Jiang F, Kim ST, et al
    Real-World Experience with (177)Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval.
    J Nucl Med. 2024;65:735-739.
    PubMed     Abstract available
    
    
    April 2024
18. NIKITAS J, Lam E, Booker KA, Fendler WP, et al
    Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
    J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004.
    PubMed     Abstract available
    
    
    
19. DUAN H, Song H, Davidzon GA, Moradi F, et al
    Prospective Comparison of (68)Ga-NeoB and (68)Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2024 Apr 25:jnumed.123.267017. doi: 10.2967/jnumed.123.267017.
    PubMed     Abstract available
    
    
    
20. GAFITA A, Djaileb L, Rauscher I, Fendler WP, et al
    RECIP 1.0 Predicts Progression-Free Survival After [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Apr 18:jnumed.123.267234. doi: 10.2967/jnumed.123.267234.
    PubMed     Abstract available
    
    
    
21. HUANG YY, Lin TC, Yang SH, Lai LS, et al
    [(177)Lu]Lu-Prostate-Specific Membrane Antigen-617 in a Patient with Metastatic Castration-Resistant Prostate Cancer and Status After Bilateral Nephrectomy.
    J Nucl Med. 2024 Apr 18:jnumed.124.267533. doi: 10.2967/jnumed.124.267533.
    PubMed    
    
    
    
22. SWIHA M, Papa N, Sabahi Z, Ayati N, et al
    Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with Quantitative SUV(mean) and Patient Outcomes.
    J Nucl Med. 2024 Apr 18:jnumed.123.267014. doi: 10.2967/jnumed.123.267014.
    PubMed     Abstract available
    
    
    
23. VISCUSE P, Devitt M, Dreicer R
    Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
    J Nucl Med. 2024 Apr 11:jnumed.123.267006. doi: 10.2967/jnumed.123.267006.
    PubMed     Abstract available
    
    
    
24. BAUCKNEHT M, Fornarini G, Di Raimondo T, Pardini M, et al
    Brain Metabolic Correlates of the Off-Target Effects of Enzalutamide on the Central Nervous System of Patients with Advanced Prostate Cancer.
    J Nucl Med. 2024 Apr 11:jnumed.124.267526. doi: 10.2967/jnumed.124.267526.
    PubMed    
    
    
    
25. HARDIANSYAH D, Yousefzadeh-Nowshahr E, Kind F, Beer AJ, et al
    Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [(177)Lu]Lu-PSMA-617 Therapy.
    J Nucl Med. 2024;65:566-572.
    PubMed     Abstract available
    
    
    March 2024
26. BERRENS AC, Sorbi MA, Donswijk ML, de Barros HA, et al
    Strong Correlation Between SUV(max) on PSMA PET/CT and Numeric Drop-In gamma-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions.
    J Nucl Med. 2024 Mar 14:jnumed.123.267075. doi: 10.2967/jnumed.123.267075.
    PubMed     Abstract available
    
    
    
27. SHI J, Li D, Chen M, Fu Y, et al
    The Value of (68)Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study.
    J Nucl Med. 2024 Mar 14:jnumed.123.266742. doi: 10.2967/jnumed.123.266742.
    PubMed     Abstract available
    
    
    
28. HARTRAMPF PE, Huttmann T, Seitz AK, Kubler H, et al
    Prognostic Performance of RECIP 1.0 Based on [(18)F]PSMA-1007 PET in Prostate Cancer Patients Treated with [(177)Lu]Lu-PSMA I&T.
    J Nucl Med. 2024 Mar 7:jnumed.123.266702. doi: 10.2967/jnumed.123.266702.
    PubMed     Abstract available
    
    
    February 2024
29. EL FAKIRI M, Ayada N, Muller M, Hvass L, et al
    Development and Preclinical Evaluation of [(211)At]PSAt-3-Ga: An Inhibitor for Targeted alpha-Therapy of Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267043. doi: 10.2967/jnumed.123.267043.
    PubMed     Abstract available
    
    
    
30. GRIFFITHS MR, Pattison DA, Latter M, Kuan K, et al
    First-in-Human (212)Pb-PSMA-Targeted alpha-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2024 Feb 29:jnumed.123.267189. doi: 10.2967/jnumed.123.267189.
    PubMed    
    
    
    
31. BOSCH D, van der Velden KJM, Oving IM, Wyndaele DNJ, et al
    The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of (223)Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
    J Nucl Med. 2024 Feb 29:jnumed.123.266654. doi: 10.2967/jnumed.123.266654.
    PubMed     Abstract available
    
    
    
32. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
    Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
    J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
    PubMed     Abstract available
    
    
    
33. MAURER T, Thomas C, Hadaschik B
    The DETECT Trial: Are We on the Verge of Precision Surgery in Primary Prostate Cancer?
    J Nucl Med. 2024 Feb 15:jnumed.123.267187. doi: 10.2967/jnumed.123.267187.
    PubMed    
    
    
    
34. KUMAR S, Crumbaker M, Emmett L
    Reply: Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2024;65:333-334.
    PubMed    
    
    
    
35. ASKARI E, Harsini S
    Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2024;65:332-333.
    PubMed    
    
    
    January 2024
36. LIGHT A, Lazic S, Houghton K, Bayne M, et al
    Diagnostic Performance of (68)Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer.
    J Nucl Med. 2024 Jan 11:jnumed.123.266527. doi: 10.2967/jnumed.123.266527.
    PubMed     Abstract available
    
    
    
37. SCHILHAM MGM, Somford DM, Kusters-Vandevelde HVN, Hermsen R, et al
    Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial.
    J Nucl Med. 2024 Jan 4:jnumed.123.266495. doi: 10.2967/jnumed.123.266495.
    PubMed     Abstract available
    
    
    
38. RAHBAR K, Boegemann M
    The Imperative for Comparative Studies in Nuclear Medicine: Elevating (177)Lu-PSMA-617 in the Treatment Paradigm for mCRPC.
    J Nucl Med. 2024 Jan 4:jnumed.123.266952. doi: 10.2967/jnumed.123.266952.
    PubMed    
    
    
    
39. UNTERRAINER LM, Ruchalski K, Allen-Auerbach MS, Calais J, et al
    PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
    J Nucl Med. 2024 Jan 4:jnumed.123.266722. doi: 10.2967/jnumed.123.266722.
    PubMed    
    
    
    
40. RAVI KUMAR AS, Hofman MS
    Unraveling the Impact of (177)Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation.
    J Nucl Med. 2024;65:85-86.
    PubMed    
    
    
    
41. STEINHELFER L, Lunger L, Cala L, Pfob CH, et al
    Long-Term Nephrotoxicity of (177)Lu-PSMA Radioligand Therapy.
    J Nucl Med. 2024;65:79-84.
    PubMed     Abstract available
    
    
    December 2023
42. DIERKS A, Gable A, Rinscheid A, Wienand G, et al
    First Safety and Efficacy Data with the Radiohybrid (177)Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer.
    J Nucl Med. 2023 Dec 21:jnumed.123.266741. doi: 10.2967/jnumed.123.266741.
    PubMed     Abstract available
    
    
    
43. BENABDALLAH N, Lu P, Abou DS, Zhang H, et al
    Beyond Average: alpha-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer.
    J Nucl Med. 2023 Dec 14:jnumed.123.266571. doi: 10.2967/jnumed.123.266571.
    PubMed     Abstract available
    
    
    
44. JADVAR H
    Sequential and Combination Therapies of (223)RaCl(2) and Prostate-Specific Membrane Antigen Radioligand Therapy.
    J Nucl Med. 2023;64:1932-1933.
    PubMed    
    
    
    November 2023
45. EMMETT L, Papa N, Counter W, Calais J, et al
    Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
    J Nucl Med. 2023 Nov 30:jnumed.123.266164. doi: 10.2967/jnumed.123.266164.
    PubMed     Abstract available
    
    
    
46. WANG F, Liu C, Vidal I, Mana-Ay M, et al
    Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted (18)F-DCFPyL PET/CT.
    J Nucl Med. 2023 Nov 30:jnumed.123.266005. doi: 10.2967/jnumed.123.266005.
    PubMed     Abstract available
    
    
    
47. KLUGE K, Einspieler H, Haberl D, Spielvogel C, et al
    Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [(68)Ga]Ga-PSMA-11 PET/CT Study.
    J Nucl Med. 2023 Nov 30:jnumed.123.266158. doi: 10.2967/jnumed.123.266158.
    PubMed     Abstract available
    
    
    
48. HERRMANN K, Rahbar K, Eiber M, Sparks R, et al
    Renal and Multiorgan Safety of (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy.
    J Nucl Med. 2023 Nov 30:jnumed.123.265448. doi: 10.2967/jnumed.123.265448.
    PubMed     Abstract available
    
    
    
49. SARTOR O, Ledet E, Huang M, Schwartz J, et al
    Prediction of Resistance to (177)Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers.
    J Nucl Med. 2023;64:1721-1725.
    PubMed     Abstract available
    
    
    October 2023
50. RAHBAR K, Essler M, Eiber M, la Fougere C, et al
    (177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study).
    J Nucl Med. 2023 Oct 12:jnumed.123.266125. doi: 10.2967/jnumed.123.266125.
    PubMed     Abstract available
    
    
    
51. MEYER C, Stuparu A, Lueckerath K, Calais J, et al
    Tandem Isotope Therapy with (225)Ac- and (177)Lu-PSMA-617 in a Murine Model of Prostate Cancer.
    J Nucl Med. 2023 Oct 5:jnumed.123.265433. doi: 10.2967/jnumed.123.265433.
    PubMed     Abstract available
    
    
    
52. TSCHAN VJ, Busslinger SD, Bernhardt P, Grundler PV, et al
    Albumin-Binding and Conventional PSMA Ligands in Combination with (161)Tb: Biodistribution, Dosimetry, and Preclinical Therapy.
    J Nucl Med. 2023;64:1625-1631.
    PubMed     Abstract available
    
    
    
53. MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al
    Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
    J Nucl Med. 2023;64:1632-1637.
    PubMed     Abstract available
    
    
    
54. GRAVES SA
    Radiation Safety Considerations of Household Waste Disposal After Release of Patients Who Have Received [(177)Lu]Lu-PSMA-617.
    J Nucl Med. 2023;64:1567-1569.
    PubMed     Abstract available
    
    
    September 2023
55. SHAGERA QA, Karfis I, Kristanto P, Spyridon S, et al
    PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
    J Nucl Med. 2023 Sep 28:jnumed.123.265874. doi: 10.2967/jnumed.123.265874.
    PubMed     Abstract available
    
    
    
56. RINSCHEID A, Gable A, Wienand G, Pfob C, et al
    An Intrapatient Dosimetry Comparison of (177)Lu-rhPSMA-10.1 and (177)Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2023 Sep 28:jnumed.123.265970. doi: 10.2967/jnumed.123.265970.
    PubMed     Abstract available
    
    
    
57. KLUGE K, Haberl D, Einspieler H, Rasul S, et al
    Antihormonal-Treatment Status Affects (68)Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer.
    J Nucl Med. 2023 Sep 21:jnumed.123.265980. doi: 10.2967/jnumed.123.265980.
    PubMed     Abstract available
    
    
    
58. SATAPATHY S, Mittal BR, Sood A, Das CK, et al
    [(177)Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial.
    J Nucl Med. 2023 Sep 14:jnumed.123.266141. doi: 10.2967/jnumed.123.266141.
    PubMed     Abstract available
    
    
    
59. KARIMZADEH A, Soeiro P, Feuerecker B, Hecker CS, et al
    Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of (177)Lu-PSMA I&T.
    J Nucl Med. 2023 Sep 7:jnumed.123.265878. doi: 10.2967/jnumed.123.265878.
    PubMed     Abstract available
    
    
    
60. MURTHY V, Gafita A, Thin P, Nguyen K, et al
    Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with (177)Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.
    J Nucl Med. 2023 Sep 7:jnumed.122.265155. doi: 10.2967/jnumed.122.265155.
    PubMed     Abstract available
    
    
    
61. KUMAR S, Crumbaker M, Harvey C, Pathmanandavel S, et al
    The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2023;64:1412-1416.
    PubMed     Abstract available
    
    
    
62. MURTHY V, Allen-Auerbach M, Lam R, Owen D, et al
    PSMA-Negative Lesion Progression Under (177)Lu-PSMA Radioligand Therapy.
    J Nucl Med. 2023;64:1502-1503.
    PubMed    
    
    
    
63. HOPE TA, Antonarakis ES, Bodei L, Calais J, et al
    SNMMI Consensus Statement on Patient Selection and Appropriate Use of (177)Lu-PSMA-617 Radionuclide Therapy.
    J Nucl Med. 2023;64:1417-1423.
    PubMed    
    
    
    August 2023
64. ZHANG J, Kang F, Gao J, Jiao J, et al
    A Prostate-Specific Membrane Antigen PET-Based Approach for Improved Diagnosis of Prostate Cancer in Gleason Grade Group 1: A Multicenter Retrospective Study.
    J Nucl Med. 2023 Aug 31:jnumed.122.265001. doi: 10.2967/jnumed.122.265001.
    PubMed     Abstract available
    
    
    
65. GRKOVSKI M, O'Donoghue JA, Imber BS, Andl G, et al
    Lesion Dosimetry for [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer.
    J Nucl Med. 2023 Aug 31:jnumed.123.265763. doi: 10.2967/jnumed.123.265763.
    PubMed     Abstract available
    
    
    
66. VAN LITH SAM, Pruis IJ, Tolboom N, Snijders TJ, et al
    PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study.
    J Nucl Med. 2023 Aug 31:jnumed.123.265738. doi: 10.2967/jnumed.123.265738.
    PubMed     Abstract available
    
    
    
67. HOHBERG M, Reifegerst M, Drzezga A, Wild M, et al
    Prediction of Response to (177)Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC.
    J Nucl Med. 2023 Aug 31:jnumed.122.264953. doi: 10.2967/jnumed.122.264953.
    PubMed     Abstract available
    
    
    
68. ALAN-SELCUK N, Beydagi G, Demirci E, Ocak M, et al
    Clinical Experience with [(225)Ac]Ac-PSMA Treatment in Patients with [(177)Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2023 Aug 24:jnumed.123.265546. doi: 10.2967/jnumed.123.265546.
    PubMed     Abstract available
    
    
    
69. EIFER M, Alipour R, Hofman MS, Ravi Kumar AS, et al
    Out with the Old, in with the New: Can We Bridge the Gap Between Clinical Trial Results Based on Bone Scans and the Era of Modern Prostate Cancer Imaging?
    J Nucl Med. 2023 Aug 17:jnumed.123.266025. doi: 10.2967/jnumed.123.266025.
    PubMed    
    
    
    
70. HOPE TA, Benz M, Jiang F, Thompson D, et al
    Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers.
    J Nucl Med. 2023 Aug 17:jnumed.123.265916. doi: 10.2967/jnumed.123.265916.
    PubMed     Abstract available
    
    
    
71. DE JONG AC, Segbers M, Ling SW, Graven LH, et al
    (68)Ga-PSMA PET/CT for Response Evaluation of (223)Ra Treatment in Metastatic Prostate Cancer.
    J Nucl Med. 2023 Aug 3:jnumed.123.265489. doi: 10.2967/jnumed.123.265489.
    PubMed     Abstract available
    
    
    July 2023
72. MELLHAMMAR E, Dahlbom M, Vilhelmsson-Timmermand O, Strand SE, et al
    Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy.
    J Nucl Med. 2023 Jul 27:jnumed.123.265523. doi: 10.2967/jnumed.123.265523.
    PubMed     Abstract available
    
    
    
73. CHEN M, Fu Y, Peng S, Zang S, et al
    The Association Between [(68)Ga]PSMA PET/CT Response and Biochemical Progression in Patients with High-Risk Prostate Cancer Receiving Neoadjuvant Therapy.
    J Nucl Med. 2023 Jul 20:jnumed.122.265368. doi: 10.2967/jnumed.122.265368.
    PubMed     Abstract available
    
    
    
74. KOLLER L, Joksch M, Schwarzenbock S, Kurth J, et al
    Preclinical Comparison of the (64)Cu- and (68)Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [(68)Ga]Ga-AMTG PET/CT.
    J Nucl Med. 2023 Jul 20:jnumed.123.265771. doi: 10.2967/jnumed.123.265771.
    PubMed     Abstract available
    
    
    
75. DUIN JJ, de Barros HA, Donswijk ML, Schaake EE, et al
    The Diagnostic Value of the Sentinel Node Procedure to Detect Occult Lymph Node Metastases in PSMA PET/CT Node-Negative Prostate Cancer Patients.
    J Nucl Med. 2023 Jul 6:jnumed.123.265556. doi: 10.2967/jnumed.123.265556.
    PubMed     Abstract available
    
    
    
76. STRAUB M, Kupferschlager J, Serna Higuita LM, Weissinger M, et al
    Dual-Time-Point Posttherapy (177)Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome.
    J Nucl Med. 2023 Jul 6:jnumed.122.264770. doi: 10.2967/jnumed.122.264770.
    PubMed     Abstract available
    
    
    
77. CARDINALE J, Giesel FL, Wensky C, Rathke HG, et al
    PSMA-GCK01: A Generator-Based (99m)Tc/(188)Re Theranostic Ligand for the Prostate-Specific Membrane Antigen.
    J Nucl Med. 2023;64:1069-1075.
    PubMed     Abstract available
    
    
    June 2023
78. HAGENS MJ, Luining WI, Jager A, Donswijk ML, et al
    The Diagnostic Value of PSMA PET/CT in Men with Newly Diagnosed Unfavorable Intermediate-Risk Prostate Cancer.
    J Nucl Med. 2023 Jun 29:jnumed.122.265205. doi: 10.2967/jnumed.122.265205.
    PubMed     Abstract available
    
    
    
79. PALMEDO H, Ahmadzadehfar H, Eschmann S, Niesen A, et al
    Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with (223)Ra: PARABO, a Prospective, Noninterventional Study.
    J Nucl Med. 2023 Jun 29:jnumed.123.265557. doi: 10.2967/jnumed.123.265557.
    PubMed     Abstract available
    
    
    
80. AH-THIANE L, Ferrer L, Rousseau C
    PSMA Is Not Specific to Prostate Cancer.
    J Nucl Med. 2023 Jun 22:jnumed.123.265720. doi: 10.2967/jnumed.123.265720.
    PubMed    
    
    
    
81. NOTOHAMIPRODJO S, Eiber M, Lohrmann C, Weber WA, et al
    Reply: PSMA Is Not Specific to Prostate Cancer.
    J Nucl Med. 2023 Jun 22:jnumed.123.265921. doi: 10.2967/jnumed.123.265921.
    PubMed    
    
    
    
82. TAUBER R, Knorr K, Retz M, Rauscher I, et al
    Safety and Efficacy of [(177)Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.
    J Nucl Med. 2023 Jun 15:jnumed.122.265259. doi: 10.2967/jnumed.122.265259.
    PubMed     Abstract available
    
    
    
83. KARIMZADEH A, Heck M, Tauber R, Solaris E, et al
    The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
    J Nucl Med. 2023 Jun 8:jnumed.122.265346. doi: 10.2967/jnumed.122.265346.
    PubMed     Abstract available
    
    
    
84. HARTRAMPF PE, Mihatsch PW, Seitz AK, Solnes LB, et al
    Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy.
    J Nucl Med. 2023 Jun 8:jnumed.122.265379. doi: 10.2967/jnumed.122.265379.
    PubMed     Abstract available
    
    
    May 2023
85. BERLINER C, Steinhelfer L, Chantadisai M, Kroenke M, et al
    Delayed Imaging Improves Lesion Detectability in [(99m)Tc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer.
    J Nucl Med. 2023 May 25:265252. doi: 10.2967/jnumed.122.265252.
    PubMed     Abstract available
    
    
    
86. KUO PH, Yoo DC, Avery R, Seltzer M, et al
    A VISION Substudy of Reader Agreement on (68)Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for (177)Lu-PSMA-617 Radioligand Therapy.
    J Nucl Med. 2023 May 25:265077. doi: 10.2967/jnumed.122.265077.
    PubMed     Abstract available
    
    
    
87. BOBBA KN, Bidkar AP, Meher N, Fong C, et al
    Evaluation of (134)Ce/(134)La as a PET Imaging Theranostic Pair for (225)Ac alpha-Radiotherapeutics.
    J Nucl Med. 2023 May 18:265355. doi: 10.2967/jnumed.122.265355.
    PubMed     Abstract available
    
    
    
88. SATAPATHY S, Sahoo RK, Bal C
    [(177)Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naive Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis.
    J Nucl Med. 2023 May 11:265414. doi: 10.2967/jnumed.123.265414.
    PubMed     Abstract available
    
    
    
89. EVANGELISTA L
    PSMA PET/CT and Therapy Response Evaluation in Metastatic Prostate Cancer: Is It Time to Surpass the Old Way?
    J Nucl Med. 2023 May 11:265308. doi: 10.2967/jnumed.122.265308.
    PubMed    
    
    
    
90. FEUERECKER B, Kratochwil C, Ahmadzadehfar H, Morgenstern A, et al
    Clinical Translation of Targeted alpha-Therapy: An Evolution or a Revolution?
    J Nucl Med. 2023;64:685-692.
    PubMed     Abstract available
    
    
    
91. BROSCH-LENZ J, Delker A, Volter F, Unterrainer LM, et al
    Toward Single-Time-Point Image-Based Dosimetry of (177)Lu-PSMA-617 Therapy.
    J Nucl Med. 2023;64:767-774.
    PubMed     Abstract available
    
    
    April 2023
92. KESLER M, Cohen D, Levine C, Sarid D, et al
    Staging Prostate Cancer with (68)Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?
    J Nucl Med. 2023 Apr 28:jnumed.122.265371. doi: 10.2967/jnumed.122.265371.
    PubMed     Abstract available
    
    
    
93. GRAEF J, Bluemel S, Brenner W, Amthauer H, et al
    [(177)Lu]Lu-PSMA Therapy as an Individual Treatment Approach for Patients with High-Grade Glioma: Dosimetry Results and Critical Statement.
    J Nucl Med. 2023 Apr 28:jnumed.122.264850. doi: 10.2967/jnumed.122.264850.
    PubMed     Abstract available
    
    
    
94. MORRIS MJ, Calais J, Czernin J
    Looking at the Future of Prostate Cancer Treatment: A Conversation Between Michael Morris, Jeremie Calais, and Johannes Czernin.
    J Nucl Med. 2023 Apr 13:265684. doi: 10.2967/jnumed.123.265684.
    PubMed    
    
    
    March 2023
95. HOTTA M, Gafita A, Murthy V, Benz MR, et al
    PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [(177)Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study.
    J Nucl Med. 2023 Mar 30:jnumed.122.265242. doi: 10.2967/jnumed.122.265242.
    PubMed     Abstract available
    
    
    
96. RAVI P, Whelpley B, Kelly E, Wolanski A, et al
    Clinical Implementation of (177)Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges.
    J Nucl Med. 2023;64:349-350.
    PubMed    
    
    
    February 2023
97. SONNI I, Dal Pra A, O'Connell DP, Ells Z, et al
    PSMA PET/CT-based Atlas for Prostatic Bed Recurrence after Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines.
    J Nucl Med. 2023 Feb 9:jnumed.122.265025. doi: 10.2967/jnumed.122.265025.
    PubMed     Abstract available
    
    
    
98. TRAPP C, Oliinyk D, Rogowski P, Von Bestenbostel R, et al
    An analysis of PSMA-PET/CT-positive lymph node distribution and their coverage by different elective nodal radiation volumes in postoperative prostate cancer patients.
    J Nucl Med. 2023 Feb 2:jnumed.122.265159. doi: 10.2967/jnumed.122.265159.
    PubMed     Abstract available
    
    
    January 2023
99. AL JALALI V, Wasinger G, Rasul S, Grubmueller B, et al
    Consecutive PSMA and AR PET imaging shows positive correlation to AR and PSMA protein expression in primary hormone naive prostate cancer.
    J Nucl Med. 2023 Jan 19:jnumed.122.264981. doi: 10.2967/jnumed.122.264981.
    PubMed     Abstract available
    
    
    
100. GUDENKAUF LM, Chavez M, Maconi ML, Geiss C, et al
     Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy.
     J Nucl Med. 2023 Jan 12:jnumed.122.264946. doi: 10.2967/jnumed.122.264946.
     PubMed     Abstract available
     
     
     
101. CALDERONI L, Maietti E, Farolfi A, Mei R, et al
     Prostate-Specific Membrane Antigen Expression on Positron Emission Tomography/Computed Tomography in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
     J Nucl Med. 2023 Jan 12:jnumed.122.264964. doi: 10.2967/jnumed.122.264964.
     PubMed     Abstract available
     
     
     December 2022
102. LUNGER L, Chantadisai M, Karimzadeh A, Rauscher I, et al
     The prognostic role of (68)Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy.
     J Nucl Med. 2022 Dec 29:jnumed.122.264962. doi: 10.2967/jnumed.122.264962.
     PubMed     Abstract available
     
     
     
103. SEIFERT R, Telli T, Hadaschik B, Fendler WP, et al
     Is (18)F-FDG PET needed to assess (177)Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis.
     J Nucl Med. 2022 Dec 15:jnumed.122.264741. doi: 10.2967/jnumed.122.264741.
     PubMed     Abstract available
     
     
     
104. SEIFERT R, Telli T, Opitz M, Barbato F, et al
     Non-specific PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scan and MRI triple validation in patients with biochemical recurrence of prostate cancer.
     J Nucl Med. 2022 Dec 2:jnumed.118.215434. doi: 10.2967/jnumed.118.215434.
     PubMed     Abstract available
     
     
     
105. PERERA M, Morris MJ
     From Concept to Regulatory Drug Approval: Lessons for Theranostics.
     J Nucl Med. 2022;63:1793-1801.
     PubMed     Abstract available
     
     
     
106. HERRMANN K, Giovanella L, Santos A, Gear J, et al
     Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center.
     J Nucl Med. 2022;63:1836-1843.
     PubMed     Abstract available
     
     
     November 2022
107. OLIVIER P, Giraudet AL, Skanjeti A, Merlin C, et al
     Phase III study of (18)F-PSMA-1007 versus (18)F-fluorocholine PET/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, cross-over, multicenter study.
     J Nucl Med. 2022 Nov 23:jnumed.122.264743. doi: 10.2967/jnumed.122.264743.
     PubMed     Abstract available
     
     
     
108. DUAN H, Ghanouni P, Daniel B, Rosenberg J, et al
     A Pilot Study of (68)Ga-PSMA11 and (68)Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer.
     J Nucl Med. 2022 Nov 17. pii: jnumed.122.264448. doi: 10.2967/jnumed.122.264448.
     PubMed     Abstract available
     
     
     
109. FRAGOSO COSTA P, Pullen L, Kesch C, Krafft U, et al
     F18-PSMA Cerenkov luminescence and flexible autoradiography Imaging in a prostate cancer mouse model and first results of a radical prostatectomy feasibility study in men.
     J Nucl Med. 2022 Nov 10. pii: jnumed.122.264670. doi: 10.2967/jnumed.122.264670.
     PubMed     Abstract available
     
     
     
110. DUAN H, Ghanouni P, Daniel B, Rosenberg J, et al
     A Pilot Study of (68)Ga-PSMA11 and (68)Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy.
     J Nucl Med. 2022 Nov 3. pii: jnumed.122.264783. doi: 10.2967/jnumed.122.264783.
     PubMed     Abstract available
     
     
     
111. WANG G, Zang J, Jiang Y, Liu Q, et al
     A single-arm, low-dose, prospective study of (177)Lu-EB-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer.
     J Nucl Med. 2022 Nov 3. pii: jnumed.122.264857. doi: 10.2967/jnumed.122.264857.
     PubMed     Abstract available
     
     
     
112. LAWAL IO, Adediran OA, Jani AB, Goyal S, et al
     Differences in Failure-free Survival Post Salvage Radiotherapy Guided by Conventional Imaging Versus (18)F-fluciclovine PET/CT in Post-prostatectomy Patients: a Post-hoc Sub-stratification Analysis of the EMPIRE-1 Trial.
     J Nucl Med. 2022 Nov 3. pii: jnumed.122.264832. doi: 10.2967/jnumed.122.264832.
     PubMed     Abstract available
     
     
     
113. JADVAR H, Abreu AL, Ballas LK, Quinn DI, et al
     Oligometastatic Prostate Cancer: Current Status and Future Challenges.
     J Nucl Med. 2022;63:1628-1635.
     PubMed     Abstract available
     
     
     October 2022
114. COOK GJR, Wong WL, Sanghera B, Mangar S, et al
     Eligibility for (177)Lu-PSMA therapy depends on the choice of companion diagnostic tracer: a comparison of (68)Ga-PSMA-11 and (99m)Tc-MIP-1404 in metastatic castrate resistant prostate cancer.
     J Nucl Med. 2022 Oct 27. pii: jnumed.122.264296. doi: 10.2967/jnumed.122.264296.
     PubMed     Abstract available
     
     
     
115. RAHBAR K, Essler M, Pabst KM, Eiber M, et al
     Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study.
     J Nucl Med. 2022 Oct 27. pii: jnumed.122.264456. doi: 10.2967/jnumed.122.264456.
     PubMed     Abstract available
     
     
     
116. KIND F, Eder AC, Jilg CA, Hartrampf P, et al
     Prognostic value of tumor volume assessment on PSMA PET after (177)Lu-PSMA radioligand therapy evaluated by PSMA PET/CT consensus statement and RECIP 1.0.
     J Nucl Med. 2022 Oct 27. pii: jnumed.122.264489. doi: 10.2967/jnumed.122.264489.
     PubMed     Abstract available
     
     
     
117. PHELPS TE, Harmon SA, Mena E, Lindenberg L, et al
     Predicting Outcomes of Indeterminate Bone Lesions on (18)F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer.
     J Nucl Med. 2022 Oct 20. pii: jnumed.122.264334. doi: 10.2967/jnumed.122.264334.
     PubMed     Abstract available
     
     
     
118. SATHEKGE M, Bruchertseifer F, Vorster M, Lawal IO, et al
     mCRPC Patients Receiving (225)Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis.
     J Nucl Med. 2022;63:1496-1502.
     PubMed     Abstract available
     
     
     September 2022
119. KARIMZADEH A, Heck M, Tauber R, Knorr K, et al
     (177)Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer: prognostic value of scintigraphic and clinical biomarkers.
     J Nucl Med. 2022 Sep 22. pii: jnumed.122.264402. doi: 10.2967/jnumed.122.264402.
     PubMed     Abstract available
     
     
     
120. JOHN N, Pathmanandavel S, Crumbaker M, Counter W, et al
     (177)Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy.
     J Nucl Med. 2022 Sep 8. pii: jnumed.122.264677. doi: 10.2967/jnumed.122.264677.
     PubMed     Abstract available
     
     
     
121. SCHOLLHAMMER R, Robert G, Asselineau J, Yacoub M, et al
     Comparison of (68)Ga-PSMA-617 PET/CT and (68)Ga-RM2 PET/CT in patients with localized prostate cancer candidate for radical prostatectomy: a prospective, single arm, single center, phase II study.
     J Nucl Med. 2022 Sep 2. pii: jnumed.122.263889. doi: 10.2967/jnumed.122.263889.
     PubMed     Abstract available
     
     
     
122. BELLAVIA MC, Patel RB, Anderson CJ
     Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic.
     J Nucl Med. 2022 Sep 2. pii: jnumed.122.264373. doi: 10.2967/jnumed.122.264373.
     PubMed     Abstract available
     
     
     
123. KLOSE JM, Wosniack J, Iking J, Staniszewska M, et al
     Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice.
     J Nucl Med. 2022;63:1357-1363.
     PubMed     Abstract available
     
     
     
124. COSTA PF, Fendler WP, Herrmann K, Sandach P, et al
     Radiation Protection and Occupational Exposure on (68)Ga-PSMA-11-Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted Prostatectomy.
     J Nucl Med. 2022;63:1349-1356.
     PubMed     Abstract available
     
     
     August 2022
125. HAGENS MJ, Oprea-Lager DE, Vis AN, Wondergem M, et al
     Reproducibility of PSMA PET/CT Imaging for primary staging of treatment-naive prostate cancer patients depends on the applied radiotracer: a retrospective study.
     J Nucl Med. 2022 Aug 25. pii: jnumed.121.263139. doi: 10.2967/jnumed.121.263139.
     PubMed     Abstract available
     
     
     
126. PATHMANANDAVEL S, Crumbaker M, Ho B, Yam AO, et al
     Evaluation of (177)Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective (177)Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
     J Nucl Med. 2022 Aug 25. pii: jnumed.122.264398. doi: 10.2967/jnumed.122.264398.
     PubMed     Abstract available
     
     
     
127. BEYER T, Czernin J, Freudenberg LS, Giesel F, et al
     A 2022 INTERNATIONAL SURVEY ON THE STATUS OF PROSTATE CANCER THERANOSTICS.
     J Nucl Med. 2022 Aug 11. pii: jnumed.122.264298. doi: 10.2967/jnumed.122.264298.
     PubMed     Abstract available
     
     
     July 2022
128. DERLIN T, Widjaja L, Werner RA, Bengel FM, et al
     (177)Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2022 Jul 19. pii: jnumed.122.264293. doi: 10.2967/jnumed.122.264293.
     PubMed     Abstract available
     
     
     
129. KOEHLER D, Sauer M, Klutmann S, Apostolova I, et al
     Feasibility of (99m)Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients.
     J Nucl Med. 2022 Jul 14. pii: jnumed.122.263892. doi: 10.2967/jnumed.122.263892.
     PubMed     Abstract available
     
     
     
130. HOFLING AA, Fotenos AF, Niu G, Fallah J, et al
     Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug.
     J Nucl Med. 2022 Jul 7. pii: jnumed.122.264299. doi: 10.2967/jnumed.122.264299.
     PubMed    
     
     
     
131. PAINDELLI C, Casarin S, Wang F, Diaz-Gomez L, et al
     Enhancing (223)Ra Treatment Efficacy by Anti-beta1 Integrin Targeting.
     J Nucl Med. 2022;63:1039-1045.
     PubMed     Abstract available
     
     
     June 2022
132. PATHMANANDAVEL S, Crumbaker M, Nguyen A, Yam AOW, et al
     The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with (177)LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
     J Nucl Med. 2022 Jun 23. pii: jnumed.122.264104. doi: 10.2967/jnumed.122.264104.
     PubMed     Abstract available
     
     
     
133. SIEBINGA H, Olde Heuvel J, Rijkhorst EJ, Hendrikx JJMA, et al
     The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on (68)Ga-PSMA-11 PET/CT in Primary Prostate Cancer Patients.
     J Nucl Med. 2022 Jun 9. pii: jnumed.122.264101. doi: 10.2967/jnumed.122.264101.
     PubMed     Abstract available
     
     
     
134. POMYKALA KL, Herrmann K, Padhani AR, Hofman MS, et al
     Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Prostate Cancer: We have the answers.
     J Nucl Med. 2022 Jun 9. pii: jnumed.122.264394. doi: 10.2967/jnumed.122.264394.
     PubMed    
     
     
     
135. SARTOR O, Herrmann K
     Prostate Cancer Treatment: (177)Lu-PSMA-617 Considerations, Concepts, and Limitations.
     J Nucl Med. 2022;63:823-829.
     PubMed     Abstract available
     
     
     
136. JADVAR H
     The VISION Forward: Recognition and Implication of PSMA-/(18)F-FDG+ mCRPC.
     J Nucl Med. 2022;63:812-815.
     PubMed     Abstract available
     
     
     May 2022
137. SARTOR O
     Invited Perspective, Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis.
     J Nucl Med. 2022 May 26. pii: jnumed.122.264128. doi: 10.2967/jnumed.122.264128.
     PubMed    
     
     
     
138. DUAN H, Baratto L, Fan RE, Soerensen SJC, et al
     Correlation of (68)Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
     J Nucl Med. 2022 May 12. pii: jnumed.122.263971. doi: 10.2967/jnumed.122.263971.
     PubMed     Abstract available
     
     
     
139. MORADI F, Duan H, Song H, Davidzon GA, et al
     (68)Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.
     J Nucl Med. 2022 May 5. pii: jnumed.122.263897. doi: 10.2967/jnumed.122.263897.
     PubMed     Abstract available
     
     
     
140. 
     FDA Approves Pluvicto/Locametz for Metastatic Castration-Resistant Prostate Cancer.
     J Nucl Med. 2022;63:13N.
     PubMed    
     
     
     April 2022
141. DENIS CES, Cousin FC, De Laere B, Hustinx R, et al
     Using, (68)Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.
     J Nucl Med. 2022 Apr 21. pii: jnumed.121.263611. doi: 10.2967/jnumed.121.263611.
     PubMed     Abstract available
     
     
     
142. GAFITA A, Rauscher I, Weber M, Hadaschik B, et al
     Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study.
     J Nucl Med. 2022 Apr 14. pii: jnumed.121.263072. doi: 10.2967/jnumed.121.263072.
     PubMed     Abstract available
     
     
     
143. KROENKE M, Schweiger L, Horn T, Haller B, et al
     Validation of (18)F-rhPSMA-7 and (18)F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
     J Nucl Med. 2022 Apr 7. pii: jnumed.121.263707. doi: 10.2967/jnumed.121.263707.
     PubMed     Abstract available
     
     
     March 2022
144. EMMETT LM, Papa N, Buteau J, Ho B, et al
     The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.
     J Nucl Med. 2022 Mar 17. pii: jnumed.121.263448. doi: 10.2967/jnumed.121.263448.
     PubMed     Abstract available
     
     
     
145. ILHAN H, Kroenke M, Wurzer A, Unterrainer M, et al
     (18)F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
     J Nucl Med. 2022 Mar 10. pii: jnumed.121.262861. doi: 10.2967/jnumed.121.262861.
     PubMed     Abstract available
     
     
     
146. HOTTA M, Gafita A, Czernin J, Calais J, et al
     Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with (177)Lu-PSMA therapy: a multicenter retrospective analysis.
     J Nucl Med. 2022 Mar 10. pii: jnumed.121.263441. doi: 10.2967/jnumed.121.263441.
     PubMed     Abstract available
     
     
     
147. NOTOHAMIPRODJO S, Eiber M, Lohrmann C, Weber WA, et al
     Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on (18)F-rhPSMA-7.3 PET/CT in patients with prostate cancer.
     J Nucl Med. 2022 Mar 3. pii: jnumed.121.263758. doi: 10.2967/jnumed.121.263758.
     PubMed     Abstract available
     
     
     
148. GONDOPUTRO W, Scheltema MJ, Blazevski A, Doan P, et al
     Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer.
     J Nucl Med. 2022 Mar 3. pii: jnumed.121.263743. doi: 10.2967/jnumed.121.263743.
     PubMed     Abstract available
     
     
     February 2022
149. WU WY, Yu F, Zhang PJ, Bu T, et al
     (68)Ga-DOTA-NT-20.3 Neurotensin receptor 1 positron emission tomography imaging as a surrogate for neuroendocrine differentiation of prostate cancer.
     J Nucl Med. 2022 Feb 17. pii: jnumed.121.263132. doi: 10.2967/jnumed.121.263132.
     PubMed     Abstract available
     
     
     
150. 
     FDA Approves New (68)Ga Kit for Prostate Cancer PET.
     J Nucl Med. 2022;63:26N.
     PubMed    
     
     
     
151. SARTOR O
     Reply: A VISION of ALSYMPCA.
     J Nucl Med. 2022;63:324-325.
     PubMed    
     
     
     
152. SCHIAVOM DUARTE P
     A VISION of ALSYMPCA.
     J Nucl Med. 2022;63:324.
     PubMed    
     
     
     
153. MEASE RC, Kang CM, Kumar V, Banerjee SR, et al
     An Improved (211)At-Labeled Agent for PSMA-Targeted alpha-Therapy.
     J Nucl Med. 2022;63:259-267.
     PubMed     Abstract available
     
     
     January 2022
154. WURZER A, Kunert JP, Fischer S, Felber V, et al
     Synthesis and Preclinical Evaluation of (177)Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
     J Nucl Med. 2022 Jan 27. pii: jnumed.121.263371. doi: 10.2967/jnumed.121.263371.
     PubMed     Abstract available
     
     
     
155. KORSEN JA, Kalidindi TM, Khitrov S, Samuels ZV, et al
     Molecular imaging of Neuroendocrine Prostate Cancer by targeting Delta-like Ligand 3.
     J Nucl Med. 2022 Jan 20. pii: jnumed.121.263221. doi: 10.2967/jnumed.121.263221.
     PubMed     Abstract available
     
     
     
156. SUTERA P, Phillips RM, Deek M, Ozyigit G, et al
     The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer - Going Beneath the Surface with Molecular Imaging.
     J Nucl Med. 2022 Jan 20. pii: jnumed.121.263684. doi: 10.2967/jnumed.121.263684.
     PubMed    
     
     
     
157. NG M, Guerrieri M, Wong LM, Taubman K, et al
     The change in management by (18)F-DCFPyL PSMA PET scanning in patients undergoing post-prostatectomy radiotherapy, with early biochemical response outcomes.
     J Nucl Med. 2022 Jan 20. pii: jnumed.121.263521. doi: 10.2967/jnumed.121.263521.
     PubMed     Abstract available
     
     
     
158. LANGBEIN T, Wang H, Rauscher I, Kronke M, et al
     Utility of (18)F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
     J Nucl Med. 2022 Jan 6. pii: jnumed.121.263440. doi: 10.2967/jnumed.121.263440.
     PubMed     Abstract available
     
     
     
159. CHEN R, Wang Y, Zhu Y, Shi Y, et al
     The Added Value of (18)F-FDG PET/CT Compared with (68)Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer.
     J Nucl Med. 2022;63:69-75.
     PubMed     Abstract available
     
     
     December 2021
160. MENA E, Rowe SP, Shih JH, Lindenberg L, et al
     Predictors of (18)F-DCFPyL-PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.
     J Nucl Med. 2021 Dec 16. pii: jnumed.121.262347. doi: 10.2967/jnumed.121.262347.
     PubMed     Abstract available
     
     
     
161. SCHUCHARDT C, Zhang J, Kulkarni HR, Chen X, et al
     Prostate-specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry.
     J Nucl Med. 2021 Dec 9. pii: jnumed.121.262713. doi: 10.2967/jnumed.121.262713.
     PubMed     Abstract available
     
     
     November 2021
162. SHAGERA QA, Artigas C, Karfis I, Critchi G, et al
     (68)Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy.
     J Nucl Med. 2021 Nov 12. pii: jnumed.121.263006. doi: 10.2967/jnumed.121.263006.
     PubMed     Abstract available
     
     
     
163. CALAIS J, Czernin J
     PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.
     J Nucl Med. 2021;62:1489-1491.
     PubMed    
     
     
     
164. SRINIVAS S, Iagaru A
     To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.
     J Nucl Med. 2021;62:1487-1488.
     PubMed    
     
     
     October 2021
165. MIYAHIRA AK, Soule HR
     The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Foundational Role of the Prostate Cancer Foundation.
     J Nucl Med. 2021 Oct 21. pii: jnumed.121.262997. doi: 10.2967/jnumed.121.262997.
     PubMed     Abstract available
     
     
     
166. SONNI I, Felker ER, Lenis AT, Sisk AE, et al
     Head-to-head comparison of (68)Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial.
     J Nucl Med. 2021 Oct 14. pii: jnumed.121.262398. doi: 10.2967/jnumed.121.262398.
     PubMed     Abstract available
     
     
     
167. CALAIS J, Czernin J, Thin P, Gartmann J, et al
     Safety of PSMA-Targeted Molecular Radioligand Therapy with (177)Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).
     J Nucl Med. 2021;62:1447-1456.
     PubMed     Abstract available
     
     
     
168. NOTNI J
     PSMA-Targeted Therapeutics: A Tale About Law and Economics.
     J Nucl Med. 2021;62:1482.
     PubMed    
     
     
     
169. EDER AC, Schafer M, Schmidt J, Bauder-Wust U, et al
     Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules.
     J Nucl Med. 2021;62:1461-1467.
     PubMed     Abstract available
     
     
     September 2021
170. FEUERECKER B, Chantadisai M, Allmann A, Tauber R, et al
     Pre-therapeutic comparative dosimetry of (177)Lu-rhPSMA-7.3 and (177)Lu-PSMAI&T in patients with metastatic castration resistant prostate cancer (mCRPC).
     J Nucl Med. 2021 Sep 16. pii: jnumed.121.262671. doi: 10.2967/jnumed.121.262671.
     PubMed     Abstract available
     
     
     
171. LEE DY, Kim YI
     Effects of (225)Ac-labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: A meta-analysis.
     J Nucl Med. 2021 Sep 9. pii: jnumed.121.262017. doi: 10.2967/jnumed.121.262017.
     PubMed     Abstract available
     
     
     
172. FOURQUET A, Rosenberg A, Mena E, Shih JJ, et al
     A comparison of (18)F-DCFPyL, (18)F-NaF and (18)F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer.
     J Nucl Med. 2021 Sep 2. pii: jnumed.121.262371. doi: 10.2967/jnumed.121.262371.
     PubMed     Abstract available
     
     
     
173. WAHL RL
     Progress in Prostate Cancer Theranostics.
     J Nucl Med. 2021;62:11N.
     PubMed    
     
     
     
174. BRENNER W, Strobel J, Prasad V
     PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?
     J Nucl Med. 2021;62:1242-1243.
     PubMed    
     
     
     August 2021
175. SEIFERT R, Sandach P, Kersting D, Fendler WP, et al
     Repeatability of (68)Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume.
     J Nucl Med. 2021 Aug 26. pii: jnumed.121.262528. doi: 10.2967/jnumed.121.262528.
     PubMed     Abstract available
     
     
     
176. PARIHAR AS, Schmidt LR, Dehdashti F, Wahl RL, et al
     Detection of additional primary neoplasms on (18)F-Fluciclovine PET/CT in patients with primary prostate cancer.
     J Nucl Med. 2021 Aug 19. pii: jnumed.121.262647. doi: 10.2967/jnumed.121.262647.
     PubMed     Abstract available
     
     
     
177. SANDHU S, Guo C, Hofman MS
     Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
     J Nucl Med. 2021 Aug 12. pii: jnumed.120.243295. doi: 10.2967/jnumed.120.243295.
     PubMed     Abstract available
     
     
     
178. LANGBEIN T, Wurzer A, Gafita A, Robertson A, et al
     The Influence of Specific Activity on the Biodistribution of (18)F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data.
     J Nucl Med. 2021 Aug 12. pii: jnumed.121.262471. doi: 10.2967/jnumed.121.262471.
     PubMed     Abstract available
     
     
     
179. 
     FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
     J Nucl Med. 2021;62:11N.
     PubMed    
     
     
     
180. 
     FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
     J Nucl Med. 2021;62:11N.
     PubMed    
     
     
     
181. CZERNIN J, Calais J
     (177)Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.
     J Nucl Med. 2021;62:1025-1026.
     PubMed    
     
     
     
182. YUSUFI N, Wurzer A, Herz M, D'Alessandria C, et al
     Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using (19)F/(177)Lu-rhPSMA-7.3 and (177)Lu-PSMA I&T.
     J Nucl Med. 2021;62:1106-1111.
     PubMed     Abstract available
     
     
     
183. FERNANDEZ R, Eppard E, Lehnert W, Jimenez-Franco LD, et al
     Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases.
     J Nucl Med. 2021;62:1126-1132.
     PubMed     Abstract available
     
     
     
184. URBAN S, Meyer C, Dahlbom M, Farkas I, et al
     Radiation Dosimetry of (99m)Tc-PSMA I&S: A Single-Center Prospective Study.
     J Nucl Med. 2021;62:1075-1081.
     PubMed     Abstract available
     
     
     July 2021
185. DIETLEIN F, Kobe C, Munoz Vazquez S, Fischer T, et al
     An (89)Zr-labeled PSMA tracer for PET/CT imaging of prostate cancer patients.
     J Nucl Med. 2021 Jul 29. pii: jnumed.121.262290. doi: 10.2967/jnumed.121.262290.
     PubMed     Abstract available
     
     
     
186. DONG L, Su Y, Zhu Y, Markowski MC, et al
     The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy.
     J Nucl Med. 2021 Jul 29. pii: jnumed.121.262411. doi: 10.2967/jnumed.121.262411.
     PubMed     Abstract available
     
     
     
187. PATHMANANDAVEL S, Crumbaker M, Yam AO, Nguyen A, et al
     (177)Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
     J Nucl Med. 2021 Jul 29. pii: jnumed.121.262552. doi: 10.2967/jnumed.121.262552.
     PubMed     Abstract available
     
     
     
188. ABGHARI-GERST M, Armstrong WR, Nguyen K, Calais J, et al
     A comprehensive assessment of (68)Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients.
     J Nucl Med. 2021 Jul 29. pii: jnumed.121.262412. doi: 10.2967/jnumed.121.262412.
     PubMed     Abstract available
     
     
     
189. BENARD F, Bratanovic IJ
     A Novel Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor Positive Prostate Cancer.
     J Nucl Med. 2021 Jul 22. pii: jnumed.120.257758. doi: 10.2967/jnumed.120.257758.
     PubMed     Abstract available
     
     
     
190. CERCI JJ, Fanti S, Lobato EE, Kunikowska J, et al
     Diagnostic performance and clinical impact of (68)Ga-PSMA-11 imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA study).
     J Nucl Med. 2021 Jul 2. pii: jnumed.120.261886. doi: 10.2967/jnumed.120.261886.
     PubMed     Abstract available
     
     
     June 2021
191. SARTOR AO, la Fougere C, Essler M, Ezziddin S, et al
     Lutetium-177-prostate-specific membrane antigen ligand following radium-223 treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience.
     J Nucl Med. 2021 Jun 24. pii: jnumed.121.262240. doi: 10.2967/jnumed.121.262240.
     PubMed     Abstract available
     
     
     
192. MIX M, Renaud T, Kind F, Nemer U, et al
     Kidney doses in (177)Lu-based radioligand therapy in prostate cancer: Is dose estimation based on reduced dosimetry measurements feasible?
     J Nucl Med. 2021 Jun 4. pii: jnumed.121.262245. doi: 10.2967/jnumed.121.262245.
     PubMed     Abstract available
     
     
     
193. MCINNES LE, Cullinane C, Roselt PD, Jackson S, et al
     Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with (67)Cu.
     J Nucl Med. 2021;62:829-832.
     PubMed     Abstract available
     
     
     May 2021
194. NICKOLS N, Anand A, Johnsson K, Brynolfsson J, et al
     aPROMISE: A Novel Automated-PROMISE platform to Standardize Evaluation of Tumor Burden in (18)F-DCFPyL (PSMA) images of Veterans with Prostate Cancer.
     J Nucl Med. 2021 May 28. pii: jnumed.120.261863. doi: 10.2967/jnumed.120.261863.
     PubMed     Abstract available
     
     
     
195. GAFITA A, Wang H, Robertson A, Armstrong WR, et al
     Tumor sink effect in (68)Ga-PSMA-11 PET: Myth or Reality?
     J Nucl Med. 2021 May 28. pii: jnumed.121.261906. doi: 10.2967/jnumed.121.261906.
     PubMed     Abstract available
     
     
     
196. CALAIS J, Gafita A, Eiber MR, Armstrong WR, et al
     Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with (177)Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.
     J Nucl Med. 2021 May 20. pii: jnumed.121.261982. doi: 10.2967/jnumed.121.261982.
     PubMed     Abstract available
     
     
     
197. BARBATO F, Fendler WP, Rauscher I, Herrmann K, et al
     PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease.
     J Nucl Med. 2021 May 14. pii: jnumed.121.262120. doi: 10.2967/jnumed.121.262120.
     PubMed     Abstract available
     
     
     
198. TREIBER H, Koenig A, Neesse A, Richter A, et al
     Liver enzyme elevation after (177)Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer.
     J Nucl Med. 2021 May 14. pii: jnumed.120.258533. doi: 10.2967/jnumed.120.258533.
     PubMed     Abstract available
     
     
     
199. ZACHERL MJ, Gildehaus FJ, Mittlmeier L, Boning G, et al
     First Clinical Results for PSMA-Targeted alpha-Therapy Using (225)Ac-PSMA-I&T in Advanced-mCRPC Patients.
     J Nucl Med. 2021;62:669-674.
     PubMed     Abstract available
     
     
     April 2021
200. FENDLER WP, Farolfi A
     REPLY: The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer.
     J Nucl Med. 2021 Apr 30. pii: jnumed.121.262271. doi: 10.2967/jnumed.121.262271.
     PubMed    
     
     
     
201. OLDE HEUVEL J, de Wit-van der Veen BJ, van der Poel HG, van Leeuwen PJ, et al
     Cerenkov Luminescence Imaging in prostate cancer: not the only light that shines.
     J Nucl Med. 2021 Apr 30. pii: jnumed.120.260034. doi: 10.2967/jnumed.120.260034.
     PubMed     Abstract available
     
     
     
202. CHEN R, Wang Y, Zhu Y, Shi Y, et al
     The added value of (18)F-FDG PET/CT compared to (68)Ga-PSMA PET/CT in patients with castration-resistant prostate cancer.
     J Nucl Med. 2021 Apr 23. pii: jnumed.121.262250. doi: 10.2967/jnumed.121.262250.
     PubMed     Abstract available
     
     
     
203. BRAVI CA, Fossati N, Gandaglia G, Suardi N, et al
     The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer.
     J Nucl Med. 2021 Apr 16. pii: jnumed.121.262104. doi: 10.2967/jnumed.121.262104.
     PubMed    
     
     
     March 2021
204. RITT P, Jobic C, Beck M, Schmidkonz C, et al
     Dissimilar DNA Damage to Blood Lymphocytes After (177)Lu-Labeled DOTATOC or Prostate-Specific Membrane Antigen Therapy.
     J Nucl Med. 2021;62:379-385.
     PubMed     Abstract available
     
     
     November 2020
205. MEIJER D, Donswijk ML, Bodar YJL, van Leeuwen PJ, et al
     Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging.
     J Nucl Med. 2020 Nov 6. pii: jnumed.120.252528. doi: 10.2967/jnumed.120.252528.
     PubMed     Abstract available
     
     
     October 2020
206. LODGE MA, Lesniak W, Gorin MA, Pienta KJ, et al
     Measurement of PET Quantitative Bias In Vivo.
     J Nucl Med. 2020 Oct 9. pii: jnumed.120.251397. doi: 10.2967/jnumed.120.251397.
     PubMed     Abstract available
     
     
     September 2020
207. FAROLFI A, Hirmas N, Gafita A, Weber M, et al
     PSMA-PET identifies PCWG3 target populations with superior accuracy and reproducibility when compared to conventional imaging: a multicenter retrospective study.
     J Nucl Med. 2020 Sep 11. pii: jnumed.120.246603. doi: 10.2967/jnumed.120.246603.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.